Literature DB >> 12467746

High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.

Anne M Connolly1, Jeanine Schierbecker, Renee Renna, Julaine Florence.   

Abstract

Daily prednisone improves strength in boys with Duchenne muscular dystrophy, but side effects are almost universal. We used a different dosing regimen of prednisone to determine if benefit to boys with Duchenne muscular dystrophy might be maintained with fewer side effects. Twice weekly oral prednisone was given each Friday and Saturday (5mg/kg/dose). This total dose is twice as high as the daily low dosage prednisone regimen (0.75 mg/kg/day). Twenty boys (8.0+/-1.2 years) were treated. Historical control groups included 18 untreated boys (6.1+/-1.6 years) and four boys (7.3+/-0.6 years) treated with daily prednisone. Strength (using a hand-held manometer and grip meter) and timed functional testing were measured. There was an improvement in upper extremity strength for 95% of boys (n=20) at 6 months using quantitative strength testing. Improvement in lower extremity strength occurred in all boys with antigravity quadriceps strength (17/17). The improvement (P=0.001 for proximal upper extremities; P=0.002 for grip; and P<0.0001 for proximal lower extremities) was significant compared to untreated boys. Sixteen boys were treated continuously for more than 12 months (22+/-1.5 months). Of these, 15 remained significantly stronger than prior to treatment and 8/16 showed additional gains in strength after six months of treatment. Six boys were on the weekly prednisolone 2 years or longer without interruption. All six had upper and lower extremity strength at follow-up that was as good or better than at baseline. Functional testing improved in boys less than 8 years without contractures. Three boys without antigravity quadriceps strength at the start of treatment lost the ability to walk unassisted within 6 months. Eight other boys lost the ability to ambulate unassisted between 12 and 24 months of treatment. In each, progressive contractures developed. Linear growth was maintained in all boys on weekly treatment. Obesity rates did not differ from untreated boys. Twice weekly prednisone improved strength over 6-12 months in the majority of boys, but did not slow contracture development. Sustained benefit beyond 12 months is possible with fewer side effects compared to daily prednisone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467746     DOI: 10.1016/s0960-8966(02)00180-3

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  42 in total

1.  A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy.

Authors:  Kristin J Krosschell; Jo Anne Maczulski; Thomas O Crawford; Charles Scott; Kathryn J Swoboda
Journal:  Neuromuscul Disord       Date:  2006-06-05       Impact factor: 4.296

2.  Two-Year Longitudinal Changes in Lower Limb Strength and Its Relation to Loss in Function in a Large Cohort of Patients With Duchenne Muscular Dystrophy.

Authors:  Abhinandan Batra; Ann Harrington; Donovan J Lott; Rebecca Willcocks; Claudia R Senesac; William McGehee; Dandan Xu; Sunita Mathur; Michael J Daniels; William D Rooney; Sean C Forbes; William Triplett; Jasjit K Deol; Ishu Arpan; Roxanne Bendixen; Richard Finkel; Erika Finanger; Gihan Tennekoon; Barry Byrne; Barry Russman; H Lee Sweeney; Glenn Walter; Krista Vandenborne
Journal:  Am J Phys Med Rehabil       Date:  2018-10       Impact factor: 2.159

3.  Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.

Authors:  D M Escolar; L P Hache; P R Clemens; A Cnaan; C M McDonald; V Viswanathan; A J Kornberg; T E Bertorini; Y Nevo; T Lotze; A Pestronk; M M Ryan; E Monasterio; J W Day; A Zimmerman; A Arrieta; E Henricson; J Mayhew; J Florence; F Hu; A M Connolly
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

Review 4.  Approaching a new age in Duchenne muscular dystrophy treatment.

Authors:  Kathryn R Wagner
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

5.  Steroid therapy and cardiac function in Duchenne muscular dystrophy.

Authors:  L W Markham; R L Spicer; P R Khoury; B L Wong; K D Mathews; L H Cripe
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

6.  Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy.

Authors:  Mattia Quattrocelli; Isabella M Salamone; Patrick G Page; James L Warner; Alexis R Demonbreun; Elizabeth M McNally
Journal:  Am J Pathol       Date:  2017-08-18       Impact factor: 4.307

Review 7.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

8.  Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy.

Authors:  Alfredo D Guerron; Rashmi Rawat; Arpana Sali; Christopher F Spurney; Emidio Pistilli; Hee-Jae Cha; Gouri S Pandey; Ramkishore Gernapudi; Dwight Francia; Viken Farajian; Diana M Escolar; Laura Bossi; Magali Becker; Patricia Zerr; Sabine de la Porte; Heather Gordish-Dressman; Terence Partridge; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

Review 9.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

10.  Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment.

Authors:  Xu Liu; Yashuo Wang; Jennifer S Gutierrez; Jesse M Damsker; Kanneboyina Nagaraju; Eric P Hoffman; Eric A Ortlund
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.